Resources

Proteomics Databases



Metabolomics Databases

• • Purified IgG or Hybridoma Cells? Selecting the Antibody Sequence Recovery Route for Your Project

  Antibody sequence recovery projects rarely fail because the binder is unknown. They fail because the team starts with the wrong material assumption. One project may have only an old IgG aliquot in the freezer. Another may still maintain a low-passage hybridoma culture with no sequence file. A third may hold a recombinant lot that must be verified before tech transfer. Each starting point supports a different recovery route.

• • Sparse VH/VL Coverage in Antibody Protein Sequencing: Digest, Purity, and LC-MS/MS Recovery Fixes

  A purified IgG sample can look acceptable on a Coomassie gel and still produce disappointing sequencing results. LC-MS/MS may run cleanly, yet variable-region coverage remains thin, CDR3 evidence is weak, or heavy-chain and light-chain assembly stops short of a usable VH/VL pair. For teams preparing recombinant expression, legacy clone rescue, or documentation submissions, sparse coverage creates immediate schedule risk.

• • From Purified IgG to VH/VL Sequence: Antibody Protein Sequencing for Legacy and Recombinant Antibodies

  Many antibody projects stall not because the binder fails functionally, but because the sequence record is incomplete. A legacy hybridoma may still produce IgG in supernatant, yet lab notebooks contain no VH or VL files. A recombinant lot may pass binding QC while the team still needs primary structure evidence for tech transfer. A comparator antibody may require documented sequence support before analytical similarity work can proceed.

• • Edman Sequencing or LC-MS/MS for N-Terminal Analysis? Matching the Method to Your Sample and QC Goal

  Introduction N-terminal analysis projects rarely fail because teams lack analytical capability. They fail because the selected method does not match the sample chemistry or the evidence standard required for the next decision. One team may need a direct ten-residue N-terminal read for lot release.

• • Scoping an Edman Sequencing Project: Sample Requirements, Cycle Count, and Report Deliverables

  Introduction Edman sequencing projects move faster when scope is defined before samples ship. Teams often request a fixed number of cycles without confirming whether the material supports that read length, whether the N-terminus is accessible, or whether the final report must satisfy internal QC, regulatory documentation, or publication standards.

• • Hybridoma Sequencing When Recovery Fails: A Practical Troubleshooting Guide

  When hybridoma recovery stalls, the priority is to determine whether the problem lies in the cells, the nucleic acid material, the amplification design, or the original project assumptions. If your team is troubleshooting a failed recovery attempt or preparing a low-passage culture for the first time, MtoZ Biolabs can Assess hybridoma readiness and recommend next steps before material is resubmitted.

• • De Novo Protein Sequencing vs Peptide Mapping: Choosing the Right Primary Structure Method

  Protein primary structure projects often begin with the same sample and very different analytical goals. One team may need to determine the sequence of an unknown purified protein. Another may need to confirm that a recombinant batch matches an expected design. A third may need QC-ready coverage evidence for an internal release file. All three projects can involve LC-MS/MS, but the best method depends on whether a reliable reference sequence already exists.

• • De Novo Protein Sequencing for Unknown Proteins: Sample Prep and Coverage Optimization

  De novo protein sequencing can recover strong primary structure evidence when the workflow is matched to the sample and coverage goal. The key is to identify why coverage is weak before resubmitting material or expanding the analytical plan. If your team is troubleshooting low peptide coverage or preparing an unknown protein sample for the first time, MtoZ Biolabs can Assess sample readiness and recommend digestion, LC-MS/MS, and validation steps before sequencing begins.

• • De Novo Protein Sequencing: How LC-MS/MS Reconstructs Full Protein Sequences Without a Reference

  Protein sequence information is often required before a research team can move forward with expression, functional validation, publication, or quality documentation. In many projects, however, no reliable reference sequence exists. The protein may come from an unannotated organism, a proprietary expression system, a legacy purified sample, or a recombinant product that has not yet been fully verified.

• • How Much Does De Novo Protein Sequencing Cost? Factors That Shape the Workflow

  Researchers evaluating de novo protein sequencing often ask for a single price before the sample details are clear. That question is understandable. Grant budgets, vendor comparisons, and project timelines all depend on cost predictability. However, de novo protein sequencing is rarely a one-size-fits-all service. The final quote depends on sample purity, protein length, coverage goal, digestion design, LC-MS/MS depth, manual interpretation, and the reporting standard required for the project.